Treatment of Lower Respiratory Tract Infections with Ceftazidime-Avibactam and Meropenem

First-Line Treatment Options

The Infectious Diseases Society recommends ceftazidime-avibactam 2.5 g IV q8h for lower respiratory tract infections caused by carbapenem-resistant Enterobacterales (CRE) 1, 2, 3
Meropenem-vaborbactam 4 g IV q8h is an alternative option for CRE infections, as suggested by the medical community 1, 3
Imipenem-cilastatin-relebactam 1.25 g IV q6h is another alternative for CRE infections, based on clinical guidelines 1, 2

For infections caused by metallo-β-lactamase (MBL)-producing organisms, combination therapy with ceftazidime-avibactam plus aztreonam is strongly recommended by medical experts 4
The medical community considers combination of ceftazidime-avibactam with a carbapenem (like meropenem) for KPC-3-producing organisms due to potential "see-saw effect" 1
Combination therapy may provide better outcomes for severe infections with high bacterial burden, particularly in critically ill patients, as suggested by clinical studies 6

Uncomplicated lower respiratory tract infections typically require 7 days of treatment 7

Antimicrobial susceptibility testing is essential to guide treatment, particularly for novel β-lactam/β-lactamase inhibitor combinations, as emphasized by medical guidelines 2
Resistance to ceftazidime-avibactam in KPC-producing organisms has been reported, particularly with prior ceftazidime-avibactam exposure, according to medical research 5
Dose adjustments are required for patients with renal impairment, as recommended by medical experts 7
Monitoring for clinical response within 48-72 hours and considering de-escalation to narrower spectrum antibiotics if susceptibility results permit is crucial, as suggested by medical guidelines 5

Avibactam does not inhibit class B metallo-β-lactamase enzymes (MBLs), making ceftazidime-avibactam ineffective as monotherapy against MBL-producing organisms, as noted by medical research 2, 3
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) considers new β-lactam/β-lactamase inhibitors as "reserved antibiotics" that should be used judiciously for extensively resistant bacteria 8
Combination therapy is not routinely recommended for all CRE infections but should be considered for specific scenarios such as MBL-producing organisms or severe infections, as recommended by medical guidelines 1, 4, 8